Liquidia Corporation $LQDA Shares Sold by Caxton Associates LLP

Caxton Associates LLP lessened its stake in Liquidia Corporation (NASDAQ:LQDA) by 24.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,075 shares of the company’s stock after selling 37,931 shares during the quarter. Caxton Associates LLP’s holdings in Liquidia were worth $4,418,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. NewEdge Advisors LLC purchased a new position in Liquidia in the second quarter valued at about $25,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Liquidia during the 4th quarter worth approximately $25,000. Covestor Ltd boosted its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares during the period. Finally, Hurley Capital LLC grew its holdings in shares of Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock worth $179,000 after acquiring an additional 3,040 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Up 2.3%

Shares of NASDAQ:LQDA opened at $89.03 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52-week low of $16.82 and a 52-week high of $90.90. The stock’s fifty day simple moving average is $70.64 and its 200-day simple moving average is $49.82. The company has a market capitalization of $7.92 billion, a P/E ratio of 635.97 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue was up 4187.1% on a year-over-year basis. As a group, equities research analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Needham & Company LLC upped their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Liquidia in a research note on Monday, May 11th. Finally, Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.62.

Insider Transactions at Liquidia

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the sale, the director directly owned 716,311 shares of the company’s stock, valued at $45,779,436.01. This trade represents a 21.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen M. Bloch sold 318,893 shares of Liquidia stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the sale, the director owned 1,870,042 shares of the company’s stock, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,022,134 shares of company stock worth $129,579,224. 25.60% of the stock is owned by insiders.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).